Ann: Appendix 4E and 2018 Annual Report, page-10

It's good we have reached the stage where CZM is actively promoting and demonstrating CONVIVO along its KINEVO product.

What bothers me with OIL's FY18 financials is the administration and R&D expense lines. They eat up all of the cash generated by revenue and yet it's hard to see what kind of return these expenses bring.

How much more R&D is required?

How come OIL is spending that much money on marketing? Carl Zeiss has already dedicated 60 sales staff to promote and sell the microscopes! I take it that marketing spend may relate to ViewnVivo, but we haven't seen much return judging by slow sales.

I'd like to see the costs reduced substantially in FY19. I expect the management to preserve cash, stop asking shareholders for more money and work out a decent strategy around ViewnVivo!